Mirum Pharmaceuticals Hits New 52-Week High of $125.09

Mirum Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 125.09 on June 29, 2026. This achievement underscores the company's remarkable performance over the past year, with a staggering increase of 381.41%, significantly outpacing the S&P 500's growth of 20.53%. As a small-cap player in the Pharmaceuticals & Biotechnology industry, Mirum Pharmaceuticals has a market capitalization of USD 5,337 million. Despite its impressive stock performance, the company remains in a loss-making position, reflected in its price-to-earnings ratio, which is not applicable. The company's financial metrics also indicate a negative return on equity of -7.42% and a debt-to-equity ratio of -0.23, suggesting a unique financial structure. The stock's previous 52-week low was recorded at USD 47.89, highlighting the significant upward trajectory it has experienced. This milestone not only marks a key point in Mirum Pharmaceuticals' journey but also reflects broader trends within the biotechnology sector.